Filing Summary
Business Context and Reporting Period
This Form 8-K was filed by Anzu Special Acquisition Corp. I on February 6, 2023, under Item 8.01, in connection with its proposed business combination with Envoy Medical Corporation, a U.S.-based medical device company. Envoy is developing an implanted cochlear device that is in early clinical testing and has received FDA Breakthrough Device Designation.
Anzu’s stockholder meeting is expected to consider an amendment extending the deadline to complete an initial business combination from March 4, 2023 to September 30, 2023, or an earlier date determined by the board.
Financial Metrics and Capitalization
- The filing does not provide revenue, profit, cash flow, margins, operating expenses, debt, liquidity balances, or other detailed financial metrics for Anzu or Envoy.
- The letter of intent reportedly includes a condition that Anzu have more than $40.0 million in its trust account immediately before any redemptions at the closing of the business combination.
- The filing does not provide the current trust-account balance, anticipated transaction consideration, financing terms, or pro forma ownership information.
Material Changes Versus the Prior Comparable Period
- Anzu and Envoy extended their mutual exclusivity arrangement on January 30, 2023, to continue working toward the proposed transaction through March 4, 2023.
- Anzu disclosed that it currently expects to file definitive transaction agreements in February 2023, execute them shortly after the stockholder meeting, and close the transaction in the first half of 2023.
- Nasdaq reserved the prospective combined company’s stock symbol, “COCH,” referring to Envoy’s planned cochlear implant.
Guidance, Outlook, Risks, and Unusual Items
- The transaction remains subject to definitive agreements, stockholder approval, regulatory approvals, satisfaction of closing conditions, and the required trust-account threshold.
- There is no assurance that definitive agreements will be executed or that the transaction will close on the anticipated timeline, or at all.
- Redemptions by Anzu’s public stockholders could reduce available transaction funding and jeopardize the trust-account condition.
- Other identified risks include failure to obtain the proposed extension, delays or failure to obtain regulatory approvals, failure to realize anticipated transaction benefits, and changing market, financial, political, legal, or business conditions.
- The filing includes an investor presentation as Exhibit 99.1 and states that Anzu intends to file a Form S-4 registration statement containing a proxy statement/prospectus relating to the proposed transaction.
Important Facts for Investors to Verify
- Whether stockholders approve the proposed extension to September 30, 2023.
- Whether Anzu and Envoy execute definitive business-combination agreements and the final transaction terms.
- The trust-account balance immediately before redemptions and the amount ultimately redeemed.
- Whether the more-than-$40.0 million trust-account closing condition is satisfied.
- Required regulatory approvals, stockholder approvals, and other closing conditions.
- Envoy’s clinical, regulatory, commercialization, financing, and operating information when provided in the Form S-4 and related filings.